Clinical Trial TitleRisk-stratified randomized phase III testing of blinatumomab (IND# I17467, NSC# 765986) in first relapse of childhood B-lymphoblastic leukemia (B-ALL).
Clinical Trial Protocol Description:
AALL 1331 is a group wide risk-stratified, randomized phase III study to test whether incorporation of blinatumomab into the treatment of patients with childhood B-lymphoblastic leukemia (B-ALL) at first relapse will improve disease free survival. Blinatumomab is being tested in this population based on its demonstrated safety profile and single agent activity (induction of MRD-negative remissions in children with multiple relapsed refractory B-ALL).
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Are between one year of age and 31 years of age at the time of relapse.
- Have had first relapse of B-ALL. Allowable sites of disease include isolated bone marrow, combined bone marrow and CNS and/or testicular, and isolated CNS and/or testicular.
This is a partial list of eligibility requirements.
Clinical Trial Investigator
Mary Lou Schmidt, MD
RUSH University Medical Center
1620 W Harrison St
Chicago, IL 60612